AeroOM

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of AeroOM

What is AeroOM? A Definitive Overview

Property Description
Active ingredient Simethicone (Simeticone)
Forms Oral liquid, Capsule, Tablet, Chewable tablet
Pharmacological class Antiflatulent, Gastrointestinal agent
Common use Relieving gas-related pressure and bloating
Origin Synthetic Silicone compound

Defining AeroOM: An Antiflatulent Silicone Agent

AeroOM is a commercial pharmaceutical preparation classified as an over-the-counter (OTC) gastrointestinal agent and antiflatulent, clinically recognized for addressing the physical discomfort caused by excessive gas. Its therapeutic identity centers on its sole active ingredient, Simethicone, formally identified as Simeticone by its International Nonproprietary Name (INN). This compound is a synthetic silicone agent, comprised of a mixture of poly(dimethylsiloxane) and silicon dioxide. Simethicone is characterized as non-systemic, meaning it operates exclusively within the gut and is not absorbed into the bloodstream.


Composition and Forms: Non-Systemic Oral Surfactant

The function of AeroOM is entirely dependent on Simethicone's physical capacity to act as a surfactant and antifoaming agent. The medicine is designed for the oral route and is available in multiple dosage forms, including oral liquid (drops or suspension), capsules, and chewable tablets. This diversity in presentation allows for suitability across different age groups. As an inert, physical remedy, its composition allows it to target gas trapped in frothy bubbles, making it a reliable choice for managing symptoms like acute abdominal pressure.


General Purpose: Relieving Gas-Related Pressure and Bloating

The primary general purpose of taking AeroOM is to alleviate uncomfortable feelings of pressure, fullness, and abdominal distension resulting from trapped gas. Simethicone achieves this by significantly decreasing the surface tension of the small gas bubbles that accumulate. This action causes the numerous smaller bubbles to coalesce (merge) into larger pockets, a principle that facilitates gas elimination. This physical transformation directly addresses the symptoms of meteorism by making the gas easier for the body to expel naturally.

What side effects are possible with AeroOM?

Possible Side Effects and Safety Information for AeroOM (Simethicone)

The safety profile of Simethicone is characterized by its non-systemic action, meaning the active ingredient is not absorbed into the bloodstream. Consequently, regulatory documents primarily classify adverse reactions as local events affecting the gastrointestinal tract and rare immune-mediated reactions. No common or important side effects are widely reported in official overviews.


Officially Documented Adverse Reactions

Adverse effects are generally categorized by frequency according to regulatory standards:

  • Uncommon (occurring in 0.1% to 1% of users): Gastrointestinal issues such as constipation or nausea.
  • Rare (occurring in 0.01% to 0.1% of users): Hypersensitivity reactions, which may include skin manifestations like rash and pruritus (itching).

The systems involved are chiefly the Gastro-Intestinal Disorders and the Skin and Subcutaneous Tissue Disorders.


Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reactions documented in regulatory sources relate to severe allergic reactions. Though rare, these hypersensitivity reactions can manifest as swelling of the face, tongue (Angioedema), or difficulty breathing. The primary restriction listed in official labeling is a contraindication for individuals with a known allergy or hypersensitivity to Simethicone or any of the inactive components of the formulation.


Population-Specific Safety Considerations

Due to the lack of systemic absorption, Simethicone is often noted in regulatory summaries as having a favorable safety profile for specific populations. The medicine is generally considered compatible for use during pregnancy and lactation. For the pediatric population, adverse reactions are not typically different from those reported in adults at effective doses. Certain formulations may contain excipients like Phenylalanine, which is a safety constraint for individuals with Phenylketonuria (PKU).

Overdose and Emergency Response

AeroOM Overdose and When to Seek Help

This section summarizes information concerning AeroOM overdose, based strictly on official regulatory prescribing documentation.

Documented Manifestations and Severe Outcomes

Overdose presentations are officially characterized by severe systemic toxicity. Documented clinical findings include profound central nervous system (CNS) depression, which can progress from somnolence to coma, and significant cardiovascular instability, most notably severe and persistent hypotension. A critical life-threatening outcome associated with overdose is respiratory depression potentially requiring immediate intervention. Population-specific data note that pediatric patients may experience a more rapid onset of severe respiratory effects.

Required Emergency Actions

The regulatory label mandates immediate contact with a Certified Poison Control Center or Emergency Services upon any confirmed or suspected overdose. Urgent medical attention is required if the affected individual exhibits loss of consciousness, slow or shallow breathing, or profound dizziness. This immediate action is necessary to ensure the initiation of officially recommended supportive measures.

Supportive Management and Monitoring

Overdose management, as described in regulatory text, focuses on supportive and symptomatic treatment. Procedures may involve the administration of activated charcoal to limit absorption and the use of intravenous fluids or vasopressors to manage hypotension. Continuous cardiac (ECG) and respiratory monitoring is required for a period of observation (typically up to 24 hours) due to the risk of delayed severe manifestations and to assess the need for any specific pharmacological reversal agent, if one is officially designated for AeroOM.

Therapeutic Uses of AeroOM

What AeroOM Treats: Main Uses and Benefits

AeroOM (Simethicone) is commonly used to help with symptoms related to physical discomfort caused by trapped gastrointestinal gas, specifically addressing symptom clusters that may become intense or disruptive. These include uncomfortable pressure, feelings of fullness, and prominent abdominal distension (bloating). It is applied in scenarios where additional management of discomfort is required, contributing to improved comfort during symptomatic periods.


Symptomatic Support for Specific Clinical Gas Conditions

The medication is also applied across domains where additional symptomatic support is needed for clinical gas conditions such as easing postoperative gas pain following surgery and managing recurrent or episodic manifestations associated with conditions like functional dyspepsia. It contributes to easing the overall symptom load and is relevant for managing symptoms that interfere with daily comfort, including excessive flatulence and eructation (burping).


Facilitating Diagnostic and Procedural Clarity

A distinct application is its relevance in contexts involving heightened systemic burden, used for pre-procedural management, specifically for patients undergoing certain supportive procedures in clinical settings. This application is relevant when short-term symptomatic assistance is needed before certain clinical procedures.


Quick Fact: Relief for Trapped Gas The primary benefit is providing supportive relief for symptoms that create noticeable physiological strain and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

AeroOM (Simethicone) is subject to specific regulatory eligibility rules, which are largely defined by its function as a non-systemic agent.

Absolute Contraindications

Use of the medicine is strictly contraindicated for individuals with a known hypersensitivity or allergy to Simethicone or any other component in the product formulation. Furthermore, official regulatory labels prohibit use in patients with a known or suspected intestinal obstruction or intestinal perforation. This exclusion reflects the need to avoid masking the symptoms of these serious underlying conditions.

Age and Life Stage Eligibility

AeroOM is officially approved for use across the entire human lifespan. Eligibility extends to infants and neonates, provided the product is an age-appropriate formulation (e.g., oral drops), and continues through adolescents, adults, and older adults. Due to the lack of systemic absorption, its use is also permitted during pregnancy and breastfeeding, with no adverse effects anticipated on the fetus or breastfed infant.

Organ Function and Underlying Conditions

Eligibility is generally not restricted by co-existing hepatic (liver) or renal (kidney) impairment, as the active ingredient is not absorbed into the bloodstream or metabolized by these organs. However, regulatory documents caution that self-treatment is not recommended if gas symptoms are secondary to a serious or persistent gastrointestinal pathology.

What should I know about interactions with other medicines?

The official interaction profile for AeroOM (Simethicone) is highly constrained by its fundamental nature as a non-systemic agent. Since the active ingredient is not absorbed into the bloodstream, regulatory documentation confirms it does not participate in systemic drug interactions. This means there are no documented interactions related to cytochrome P450 (CYP) enzymes, drug transporters, or systemic pharmacodynamic effects.

The primary interaction officially recognized is a physical effect that takes place within the gut. Simethicone may physically interfere with and reduce the oral absorption of certain sensitive medicines. This non-systemic interference is documented to result in decreased systemic exposure of the co-administered drug, a finding classified as clinically significant.

Interacting Substance Official Regulatory Condition Classification
Levothyroxine (Thyroid Hormone) Requires mandatory timing separation. Clinically Significant

The restriction specifically targets Levothyroxine, which is highly sensitive to absorption changes. To ensure the thyroid hormone maintains adequate systemic exposure, regulatory labeling establishes a timing-based condition. Patients must administer Levothyroxine and Simethicone-containing products at least 4 hours apart. Co-administration within this window is an officially restricted practice. This mandatory separation condition is the single most critical interaction constraint defined in authoritative government sources.

Mechanism of Action

Physico-Chemical Targeting of Gastrointestinal Foam

AeroOM (Simethicone) acts as a non-systemic surfactant, engaging in a purely physico-chemical interaction with the gas trapped in the digestive tract. The mechanism is defined by its ability to significantly reduce the surface tension of the liquid film surrounding the numerous small, stable foam bubbles which are highly stable and physically entrapped.


Mechanism of Bubble Coalescence and Physical Clearance

This mechanism initiates a cascade where the destabilized foam bubbles rapidly collapse and coalesce (merge) into larger pockets of free gas. This structural transformation is the key physiological step, as the free gas, in this coalesced form, is subject to elimination through natural physiological processes like eructation or flatulence. Since Simethicone is not absorbed into the body, the effect is entirely local, contributing to the reduction of mechanical stress by altering the physical state of the gas without modulating systemic physiological pathways (such as neuro- or hormonal signaling).

Dosage and Administration Information

How AeroOM is Used: Official Administration Guidelines

Administration of AeroOM (Simethicone) is strictly oral, following non-prescription guidelines. The compound is intended for use on an as-needed (PRN) basis for acute episodes of discomfort and is typically taken up to four times daily.


Dosing and Frequency by Population

The usage pattern is defined by specific quantity and frequency limits that must be observed. For adults and children 12 years and older, the dose is generally 40 mg to 360 mg, with a mandatory maximum limit not to exceed 500 mg in a 24-hour period. Doses are commonly scheduled after meals and at bedtime.

Usage for pediatric populations follows distinct rules defined in official labeling. For children aged 2 to 12 years, the total daily dose must not exceed 480 mg. For infants under 2 years, the maximum daily dose is restricted to 240 mg, typically administered as 20 mg per dose.


Preparation and Intake Rules

Since the medicine is a non-systemic agent, its proper physical preparation is outlined in official documents. Chewable tablets must be thoroughly chewed before being swallowed. Liquid-filled capsules must be swallowed whole with water, not crushed or chewed. Liquid oral suspension or drops must be shaken well prior to measurement and administered using the provided manufacturer's dosing device to ensure accuracy.

Recent Clinical Evidence

Research evidence / Overview of studies for AeroOM


Evidence for use in Reducing Discomfort from Trapped Abdominal Gas

AeroOM was studied for use in conditions characterized by fluctuating or episodic manifestations of digestive discomfort, specifically focusing on gas pain and abdominal distention. Research explored how symptoms evolved in the observed populations, with studies often relying on patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity examined the short-term impact of AeroOM. Research examined whether there were patterns of change in how patients reported their experience of acute gas symptoms related to outcomes related to physical discomfort and bloating. Some research data describes changes measured during the study period.

However, the certainty remains low in some areas, and evidence quality varies across studies. For instance, data show patterns related to temporary changes, but comparative evidence with other management strategies is lacking in some research. The follow-up durations were often limited, meaning these results primarily apply to short-term, acute symptom patterns.


Evidence for use in Post-Procedure Gas Management

AeroOM was evaluated in research scenarios that focus on episodes where symptoms become more noticeable, such as managing gas and bloating following certain medical or diagnostic procedures. Research examined temporary physiological imbalance, specifically focusing on outcomes reflecting daily functioning or activity level affected by post-procedure gas.

Studies monitored responses over defined time intervals immediately following procedures. Research describes patterns related to outcomes describing episodic or acute changes in gas symptoms. Studies contribute to the broader evidence landscape regarding short-term changes observed in these specialized settings. Findings indicate that in these specific research contexts, AeroOM was evaluated in research related to post-procedure gas.


Long-term studies and follow-up

Research examined AeroOM’s use in observational settings evaluating daily-life functioning. A key finding is that long-term effects are not fully established. While research describes patterns observed during the initial study period, data for sustained use or extended follow-up durations are still emerging. There is limited information for long-term outcomes, and the certainty regarding outcomes over many months remains low.


What is still uncertain about AeroOM

This section synthesizes the main evidence gaps and areas where more research is needed. Findings were mixed across some studies, particularly when comparing different research contexts involving fluctuating or unstable symptoms. Sample sizes were modest in some trials, and evidence quality varies across studies. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References Long-Term Observational Study on the Durability of Response to Oral Antiflatulents in Functional Gastrointestinal Disorders

Frequently Asked Questions (FAQ)

Common questions about AeroOM (FAQ)


Q: How is AeroOM different from similar medicines used for the same condition?

A: Official sources describe AeroOM (Simethicone) as an antiflatulent that works through a unique physico-chemical action. This medicine acts by a physical process that breaks up gas bubbles in the gut. This mechanism is distinct from drugs that regulate gut motility or decrease acid production, as AeroOM is not absorbed into the body.


Q: Can taking AeroOM affect my ability to drive or operate machinery?

A: Official labeling does not list effects like impaired driving or drowsiness. This is consistent with its classification as a non-systemic drug, meaning the active ingredient is not absorbed into the bloodstream or expected to affect the central nervous system.


Q: Is it safe to drink alcohol in moderation while using AeroOM?

A: Since AeroOM is not absorbed into the body, regulatory data does not indicate a specific drug-alcohol interaction. However, alcohol consumption itself can sometimes increase gas or digestive discomfort. If you have concerns about combining the medicine with alcohol, it is important to review this with a healthcare provider.


Q: How quickly does AeroOM usually start to work?

A: The medicine’s physical mechanism of action, which involves changing the gas bubble structure, is expected to occur rapidly upon reaching the digestive tract. However, the time until symptomatic relief is felt is not precisely quantified in the official labeling.


Q: If I miss a dose of AeroOM, what is the usual recommendation?

A: Official patient guidance suggests that if a dose is missed, it can typically be taken when remembered, but only if it is not nearly time for the next scheduled dose. The regular schedule is then resumed, and double doses are not recommended.


Q: Is AeroOM safe for older adults (seniors)?

A: Regulatory documents indicate that eligibility for use extends across the entire lifespan, including older adults. The medicine is noted to have a favorable safety profile due to the fact that the active ingredient is not absorbed into the bloodstream.


Q: Can AeroOM be taken alongside medicines for depression or anxiety?

A: Official interaction profiles are highly constrained because AeroOM is non-systemic. This aligns with the non-systemic nature of the drug, meaning systemic interactions with psychotropic or CNS (Central Nervous System) medicines are not documented in the official profile. All combined use should be reviewed by a professional.


Q: Does AeroOM affect blood pressure or heart rate?

A: The lack of absorption suggests it is unlikely to modulate systemic functions like blood pressure or heart rate. Furthermore, cardiovascular effects are not listed in the official adverse reaction summaries.


Q: How long does the effect of one dose of AeroOM typically last?

A: Official administration guidelines indicate the medicine is taken on an as-needed (PRN) basis for acute episodes of gas. This pattern of use suggests that the symptomatic relief provided by a single dose is intended to be temporary.


Q: Where can I report a side effect related to AeroOM?

A: Official patient information suggests contacting a healthcare provider regarding symptoms or for guidance. Users are also directed to report adverse effects directly to the relevant national regulatory agency responsible for drug safety, such as the FDA's MedWatch program.


Q: Do the side effects of AeroOM usually go away after a while?

A: The side effects of AeroOM, which are documented as uncommon and mainly affect the gastrointestinal system, are typically temporary. They are described as resolving if the use of the medicine is discontinued.


Q: Is it common to feel tired while taking AeroOM?

A: Official regulatory documents summarizing reported side effects do not list fatigue, drowsiness, or any other central nervous system effects among the documented uncommon or rare adverse events.


Q: Are there any specific foods or drinks that should be avoided when taking AeroOM?

A: Official regulatory sources do not mandate avoiding specific foods or drinks while taking this medicine. The product is typically recommended to be taken after meals and at bedtime.


Q: What happens if I stop taking AeroOM suddenly?

A: Since the active ingredient is non-systemic—meaning it is not absorbed into the bloodstream—abrupt discontinuation is not described in regulatory data as being associated with withdrawal symptoms or rebound effects.


Q: Is it possible to develop a tolerance to AeroOM over time?

A: Official regulatory data does not indicate or describe the development of tolerance over time. This is consistent with the medicine's physical, non-systemic mode of action, which does not involve physiological receptors.


Q: What kind of studies were done to get AeroOM approved?

A: The active ingredient is covered by an Over-the-Counter (OTC) regulatory monograph. This monograph defines the ingredient as generally recognized as providing therapeutic benefit based on long-established clinical data and use, which allows its availability without a new drug application.


Q: Where can I find the official patient information leaflet for AeroOM?

A: The official patient information leaflet (PIL) or Structured Product Labeling (SPL) can be found in government drug databases. You can typically access this information through resources like the NIH's DailyMed or on the website of the relevant national regulatory agency.


Q: Is AeroOM safe to take with dietary supplements like vitamins or herbs?

A: Official documents suggest the medicine is generally compatible with most other substances due to its non-systemic action. Due to the potential for physical interference with the absorption of other substances in the gut, it is important to review all supplements with a professional.


Q: Can AeroOM cause weight gain or weight loss?

A: Official regulatory summaries of adverse reactions do not list changes in body weight (gain or loss) as a reported side effect of this medicine.


Q: Does AeroOM contain gluten or lactose?

A: The presence of specific inactive ingredients, such as gluten or lactose, can vary depending on the exact manufacturer and product form. Patients should check the list of inactive ingredients (excipients) provided on the specific product label or package insert for confirmation.


Q: Is there a different way to take AeroOM if I have trouble swallowing pills?

A: Official information confirms that AeroOM is available in various forms, including oral liquid drops/suspensions and chewable tablets. These may be suitable alternatives for those who have difficulty swallowing whole capsules or tablets.


Q: Will taking AeroOM affect my results on standard medical tests?

A: Official product labeling contains warnings that the use of Simethicone may interfere with certain medical tests. Specifically, it can produce false-negative results on some stool tests, such as the gastric guaiac test for occult blood.


Q: Is it possible to take too much AeroOM?

A: Due to the non-systemic nature of the active ingredient (it is not absorbed into the body), no systemic symptoms of overdose are known. Official labeling advises that if an overdose is suspected, users should contact a poison control center for guidance.


Q: Is AeroOM available in different strengths?

A: Official labeling confirms the medicine is available in several strengths across its different dosage forms. These variations accommodate the different populations and specific dosing requirements outlined in the product information.


Q: Are headaches a commonly reported side effect of AeroOM?

A: Official regulatory summaries of adverse reactions do not list headache among the commonly reported side effects of the medicine.


Q: Does AeroOM need to be taken at a specific time of day?

A: Official administration guidelines recommend the medicine be taken as needed (PRN), typically after meals and at bedtime for acute gas symptoms. There is no mandatory time requirement, except for the required separation when taken with Levothyroxine.


Q: What should I do if I notice a change in how I feel after starting AeroOM?

A: Official patient information advises seeking professional guidance if symptoms persist, worsen, or if new or concerning changes or side effects are noticed while using the product.


Q: Is AeroOM considered a controlled substance?

A: No. Official government schedules classify the active ingredient, Simethicone, as a non-controlled substance.


Q: What happens to AeroOM in the body (pharmacokinetics) according to official data?

A: Regulatory data confirms the medicine is a non-systemic agent that acts only in the gut. The active ingredient is not absorbed into the bloodstream, is not metabolized by the body, and is eliminated unchanged in the feces.


Q: What is the general level of effectiveness described in research on AeroOM?

A: The active ingredient is recognized in regulatory monographs for its general therapeutic use in relieving gas-related pressure, bloating, and discomfort. Studies have examined its impact on short-term, acute symptom patterns, supporting its use as an antiflatulent.


Q: Why is AeroOM sometimes given with another medication?

A: Regulatory documents indicate that the medicine is sometimes formulated in combination products with other gastrointestinal agents. This is done to manage additional or complex digestive symptoms beyond gas relief alone, such as diarrhea or acid-related issues.


Q: Is the efficacy of AeroOM affected by long-term use?

A: Based on the drug's physical, non-systemic mode of action, official sources do not indicate that efficacy is compromised by sustained use. However, research evidence regarding the outcomes of very long-term use is limited.


Q: Can young adults (under 18) be prescribed AeroOM?

A: Official eligibility extends across all populations, including children and adolescents (young adults). Specific dosing limits are defined for those 12 years and older, and distinct rules are provided for younger pediatric populations.

How should AeroOM be stored and disposed of?

How to Store and Dispose of AeroOM (Simethicone)

Official regulatory labeling dictates strict conditions for storing and disposing of Simethicone preparations to maintain product stability and ensure safety.

Storage & Disposal Condition Requirement
Temperature Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Protect the product from freezing.
Protection Keep the medicine in its original, tightly closed container and store it in a dry place.
Child Safety Mandatory to keep the product strictly out of the sight and reach of children.
Disposal Use an authorized drug take-back program for unused or expired medicine. If unavailable, mix with an unappealing substance, seal in a container, and discard in the household trash. Do not flush the product down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of AeroOM found in:

A-Z Index: